SCHEMBL6785482

SCHEMBL6785482

COC(=O)c1cc(OC)c(OC)c(OC)c1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.53
KDM4E B2RXH2 4/20 0.52
POLB P06746 2/20 0.52
USP2 O75604 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ABCG2 Q9UNQ0 4/20 0.46
ABCB1 P08183 1/20 0.46
LTB4R Q15722 1/20 0.45
THRB P10828 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
ALDH1A1 P00352 3/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784312 0.92 TERT (0.61) TERTKDM4EPOLBUSP2HSD17B10
SCHEMBL6791393 0.85 TERT (0.57) TERTKDM4EPOLBLTB4RALDH1A1
SCHEMBL6781638 0.84 TERT (0.61) TERTKDM4EPOLBHSD17B10LTB4R
SCHEMBL6790307 0.81 TERT (0.58) TERTKDM4EPOLBHSD17B10LTB4R
SCHEMBL6787356 0.80 TERT (0.58) TERTKDM4ELTB4RALDH1A1LMNA
SCHEMBL6784696 0.79 TERT (0.67) TERTKDM4EHSD17B10LTB4RALDH1A1
SCHEMBL6784219 0.79 TERT (0.78) TERTKDM4EHSD17B10LTB4RALDH1A1
SCHEMBL6786058 0.79 TERT (0.67) TERTKDM4ELTB4RALDH1A1HPGD
SCHEMBL6784143 0.79 TERT (0.57) TERTKDM4EPOLBLTB4RALDH1A1
SCHEMBL6782055 0.78 TERT (0.65) TERTKDM4EPOLBHSD17B10LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885KDM4E 1243/4885POLB 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.